Eisai: FDA Action Is Robbing Belviq of Exclusivity
By Mari Serebrov
Monday, August 12, 2013
The FDA jumped the gun on clocking the five-year exclusivity of Belviq from the date it granted approval a move that would rob the obesity drug of nearly a year of exclusivity, Eisai Inc. claimed in a recent citizen petition that asks the agency to reset the clock.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.